Crystalline form E of tafamidis meglumine, process for preparation and use thereof
US10577334B2 · kind B2 · utility
1Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 5, 2017 |
| Grant date | Mar 3, 2020 |
| Priority date | — |
| Expiry date | May 5, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to a novel crystalline form E of Tafamidis meglumine, process for preparation and use thereof. When compared with prior crystalline forms, the novel crystalline form of the present disclosure has the advantages of simple process and low hygroscopicity, which provides a new and better choice for the development of Tafamidis meglumine drug product and is of great significance.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.